The International Hyperhidrosis Society was founded in 2003 by a group of dedicated physicians and medical professionals with a commitment to scientific rigor in hyperhidrosis and related fields. As part of that commitment, we keep an extensive inventory of published scientific literature relevant to hyperhidrosis and share it with you, here. We believe it's vital to review published clinical data whenever discussing or reporting on health and hyperhidrosis and we strongly encourage product and treatment development teams to conduct rigorous testing and to espouse only that which can be validated.
Below you will find chronological links to articles, posters, and study data representing the most current peer-reviewed medical and scientific information available on the physiology, treatment, and effects of hyperhidrosis. New data will be posted as it becomes available. Use this rich library of research to inform your decisions and perceptions.
Are you working on research in hyperhidrosis? We can help in many ways!
And, as always, your donations are vital to our continued, collective work toward better care, improved lives, and greater understanding.
We do our best to scour all publications and post hyperhidrosis research here, but if we have missed something, please let us know. We will be happy to include it!
Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health and Quality of Life Outcomes. 2017 15:121.
Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population. Abstract (5192) presented at American Academy of Dermatology March 2017, Late-Breaking Research: Clinical Studies/Pediatric (F072).
Pariser D, Krishnaraja J, Tremblay T, Rubison M, Love T, McGraw B. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis. Journal of Drugs in Dermatology 2017 Feb 1;16(2): 127-132.
Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. American Academy of Physical Medicine and Rehabilitation. 2016 Oct 22. pii: S1934-1482(16)31056-5.
Muthusamy A, Gajendran R, Ponnan S, Thangavel D, Rangan V. A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(6):CC08-CC10.
Glaser D, Ballard A, Hunt N, Pieretti L & Pariser D. Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey. Dermatol Surg 42:12 (2016): 1347-1353.
Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS One doi: 10.1371/journal.pone.0153719. Published online April 22, 2016.
Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal adults. JAMA Neurol. doi:10.1001/jamaneurol.2016.0508. Published online April 18, 2016.
Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, et al. (2015). Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. British Journal of Dermatology, 173: 1163-1168. doi: 10.1111/bjd.13973
Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 13:4 (2014): 449-456.
Pinson I et al. Non-invasive short-wave guided radiofrequency device for long-term sweat reduction in patients with primary axillary hyperhidrosis: a preliminary study, presented at the 34 ASLMS Annual Conference, April 4-6, 2014, Phoenix, AZ.
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Aug;6(80): 811-21.
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 38 (2012): 185-191.
Swaile DF et al. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol 166 Suppl. 1 (2012): 22-26.
Wang F et al. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 124:21 (2011): 3495-3498.
Woolery-Lloyd H, Valins W. Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis. Cutis 88:1 (2011): 43-45.
Doft MA, et al. Treatment of axillary hyperhidrosis with botulinum toxin: a single surgeon's experience with 53 consecutive patients. Aesthetic Plast Surg 2011 May 11.
Lupin M et al. A multi-center evaluation of the miradry system to treat subjects with axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.
Kilmer S et al. A randomized, blinded clinical study of a microwave device for treatment of axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.
Wait SD. et al. Thoracoscopic sympathectomy for hyperhidrosis: analysis of 642 procedures with special attention to horner’s syndrome and compensatory hyperhidrosis. Neurosurgery 67:3 (2010): 652-657.
Kaminer MS et al. First clinical use of a novel microwave device for treatment of axillary hyperhidrosis, presented at the American Society for Dermatologic Surgery 2010 Annual Meeting, October 21-24, 2010, Chicago, IL.
Marques AH et al. Evaluation of stress symptoms by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. Neuroimmunomodulation 17:3 (2010): 205-208.
Cantarella G et al. Treatment of Frey’s syndrome with botulinum toxin B. Otolaryngol Head Neck Surg 143 (2010): 214-218.
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treatment of axillary hyperhidrosis, presented at the 2010 ASDS/ASCDAS Joint Annual Meeting, October 21-24, 2010, Chicago, IL.
Hill S. Hyperhidrosis Diagnosis and Management. Pediatric Rounds, a newsletter from the physicians of Children's Specialty Group, (Fall 2010) 12-14.
Shams K, Kavanagh GM. Immediate reduction in sweat secretion with electric current application in primary palmar hyperhidrosis. Archdermatol doi: 10.1001/archdermatol.2010.300.
Milanez de Campos JR et al. Comparison of pain severity following video-assisted thoracoscopic sympathectomy: electric versus harmonic scalpels. Interactive Cardiovascular and Thoracic Surgery 10 (2010): 919-922.
Wolosker N et al. Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis. Journal of Vascular Surgery 51:5 (2010): 1190-1194.
Mujica-Parodi LR et al. Chemosensory cues to conspecific emotional stress activate amygdale in humans. PLoS One doi: 10.1371/journal.pone.0006415.
Prehn-Kristensen A et al. Induction of empathy by the smell of anxiety. PLoS One doi: 10.1371/journal.pone.0005987.
Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. Journal of Drugs in Dermatology 8:5 (2009): 477-480.
Jones T et al. Safety and tolerability of topical botulinum toxin type A in healthy adults, presented at the 69th Annual Meeting of the Society for Investigative Dermatology, May 2009, Montreal, Canada.
American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products, Schaumburg, IL, April 2009.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol doi: 10.1016/j.jaad.2009.02.038.
Keller SM et al. Diagnosis of palmar hyperhidrosis via questionnaire without physical examination. Clin Auton Res doi: 10.1007/s10286-009-0006-5.
Grunfeld A et al. Botulinum toxin for hyperhidrosis. Am J Clin Dermatol 10:2 (2009): 87-102.
Miller DL et al. Effect of sympathectomy level on the incidence of compensatory hyperhidrosis after sympathectomy for palmar hyperhidrosis. J Thorac Cardiovasc Surg 138 (2009): 581-585.
Cruz J et al. Effects of endoscopic thoracic sympathectomy for primary hyperhidrosis on cardiac autonomic nervous activity. The Journal of Thoracic and Cardiovascular Surgery 137:3 (2009): 664-669.
Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 160:3 (2009): 721-722.
Gelbard CM et al. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatric Dermatology 25:6 (2008): 591-598.
Kossintseva I, Barankin B. Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. Journal of Cutaneous Medicine and Surgery 12:4 (2008): 189-193.
Efthymiou CA, Thorpe JAC. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. European Journal of Cardio-thoracic Surgery 33 (2008): 1157-1158.
Hartl DM, et al. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). The Journal of Laryngology & Otology 122 (2008): 1100-1104.
Honeyman JF et al. Efficacy of botulinum toxin for a congenital eccrine naevus. J Eur Acad Dermatol Venereol 22:10 (2008): 1275-1276.
Flanagan KH et al. Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. Journal of Drugs in Dermatology 7:3 (2008): 221-227.
Smalls LK et al. Clinical comparison of otc products labeled prescription strength wetness protection to prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Smalls LK et. al. Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
de Bree R et al. Management of Frey syndrome. Head & Neck 29:8 (2007): 773-778.
Na GY et al. Control of palmar hyperhidrosis with a new 'dry-type' iontophoretic device. Dermatol Surg 33 (2007): 57-61.
Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. Dermatol Surg 33 (2007): 908-923.
Bechara FG et al. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33 (2007): 924-927.
NAD Examines Advertising for P&G's Secret Clinical Strength, NAD News, National Advertising Review Council, New York, NY, July 2007.
Glaser DA et al. Primary focal hyperhidrosis: scope of the problem. Cutis 79:suppl 5 (2007): 5-17.
Glaser DA et al. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 18-28.
Glaser DA et al. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 29-32.
Ram R et al. Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. Cosmetic Dermatology 79 (2007): 281-288.
Glaser DA et al. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Kessler E et al. A demographical study of hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Glaser DA et al. 4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Thomas M et al. Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Aghaei S. Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population. The International Society of Dermatology 46 (2007): 212-214.
Lear W et al. An epidemiological study of hyperhidrosis. Dermatol Surg 33 (2007): S69-S75.
Talarico-Filho S et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 (2007): S44-S50.
Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 (2007): S76-S80.
Barankin B et al. Treatment of inguinal hyperhidrosis with botulinum toxin type A. International Journal of Dermatology 45 (2006): 985-986.
Kavanagh GM, Shams K. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. Journal of the American Academy of Dermatology 55:5 (2006): S115-S117.
Kavanagh GM et al. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. British Journal of Dermatology 155:2 (2006): 487.
Pariser D et al. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Thomas M et al. Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Hamm H et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006 212 (2006): 343-353.
Moya J et al. Thoracic sympathicolysis for primary hyperhidrosis. Surg Endosc 20 (2006): 598-602.
Weber A et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. British Journal of Dermatology, (2005) 152: 342–345.
Glaser DA et al. Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Kowalski JW et al. Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Neumayer C et al. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 140: 676-680 (2005).
Eisenach JH et al. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clinic Proceedings 80:5 (2005): 657-666.
Solish N et al. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:4 (2005): 405-413.
Cliff SH, Reeken S. Axillary hyperhidrosis and botox responding to demands: starting a nurse-led service. Nurse2Nurse 5:1 (2005): 28-30.
Krogstad AL et al. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152:2 (Feb 2005): 329-333.
Haider A, Solish N.Focal hyperhidrosis: diagnosis and management. CMAJ 172:1 (2005): 1-7.
Lowe N et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151:6 (Dec 2004): 1115-1122.
Lee J et al. A case of foul genital odor treated with botulinum toxin A. Dermatologic Surgery doi: 10.1111/j.1524-4725.2004.30382.x.
Campanati A et al. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.
Strutton D et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.
Hornberger J et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Journal of the American Academy of Dermatology 51:2 (2004): 274-286.
Glaser DA et al. Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Dolianitis C et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australasian Journal of Dermatology 45 (2004): 208-212.
Kavanagh GM et al. Botox® delivery by iontophoresis. British Journal of Dermatology 151 (2004): 1093-1095.
Ojimba TA, Cameron AEP. Drawbacks of endoscopic thoracic sympathectomy. British Journal of Surgery 91 (2004): 264-269.
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (English, without graphs)
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (German, with graphs)
Hexsel DM et al. Inguinal, or hexsel’s hyperhidrosis. Clinics in Dermatology 22 (2004): 53-59.
Atkinson JLD, Fealey RD. Sympathotomy instead of sympathectomy for palmar hyperhidrosis: minimizing postoperative compensatory hyperhidrosis. Mayo Clinic Proceedings 78:2 (2003): 167-172.
Gossot D et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thoracic Surg 75 (2003): 1075-1079.
Naumann M et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months. Arch Dermatol 139 (2003): 731-736.
Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg 28:6 (2002): 495-499.
Davidson JRT et al. Hyperhidrosis in social anxiety disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002): 1327-1331.
Naumann MK et al. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Brit J Dermatol 147 (2002): 1218-1226.
Glent-Madsen L, Dahl JC. Axillary hyperhidrosis: local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 (1988): 87-89.